Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One

Executive Summary

In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.

You may also be interested in...

FDA Raises Profile Of “Bad Ad” Program With Its Own Ads

The agency continues to publicize the program for health care professionals and the public to report misleading drug promotion.

Small Companies Turning To CDER Ombudsman For Help With Drug Approvals

While the CDER ombudsman dealt with far fewer complaints overall in 2011 than in 2010 due to administrative changes, smaller companies are increasingly asking for help in certain key areas of drug development.

Merck’s Saphris Gets FDA Letter After Taking Informant To Lunch

A complaint to the “Bad Ad” program that a speaker had promoted an unapproved use for Merck’s atypical antipsychotic Saphris leads FDA’s Office of Prescription Drug Promotion to issue a “notice of violation” letter.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts